Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance
Sponsor: Array BioPharma
Terminated
poor enrollment
This PHASE2 trial investigates Clinical Stage III Cutaneous Melanoma AJCC V8 and Clinical Stage IV Cutaneous Melanoma AJCC V8 and is currently terminated or withdrawn. Array BioPharma leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Jan 2025 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Jul 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Array BioPharma
- Bristol-Myers Squibb
- Jonsson Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .